Hepatitis C

@article{Wong2012HepatitisC,
  title={Hepatitis C},
  author={John B. Wong},
  journal={PharmacoEconomics},
  year={2012},
  volume={24},
  pages={661-672}
}
  • J. Wong
  • Published 2012
  • Medicine
  • PharmacoEconomics
Chronic hepatitis C virus (HCV) infection affects 170 million individuals worldwide. As it is detected incidentally through the evaluation of liver function tests or at the time of blood donor testing, it is usually clinically silent until the advanced stages of liver disease have occurred, when treatment is less effective and shortages of donor liver organs limit the therapeutic options. Combination therapy with ribavirin and pegylated interferon has resulted in sustained viral negative… Expand
Treatment costs of hepatitis C infection among injection drug users in Canada, 2006-2026.
TLDR
Given the lack of effective HCV prevention strategies in Canada, targeted evidence-based responses to prevent HCV transmission and ensure appropriate allocation of medical resources to meet the present and future treatment needs of HCV-infected IDUs are needed. Expand
Estimation of average diagnosis and treatment costs of hepatitis C
TLDR
The average cost of diagnosis and treatment of hepatitis C among patients based on their treatment regime, during the one course of treatment and six-month after stopping that is estimated. Expand
The role of insurance providers in supporting treatment and management of hepatitis C patients
TLDR
Hepatitis C virus disease requires serious policies and affordable insurance coverage and the expansion of coverage by private payers seems able to generate positive spillover benefits to public insures. Expand
[Extrahepatic manifestations in chronic hepatitis C infected patients].
TLDR
The authors summarize the main extrahepatic manifestations of chronic hepatitis C, as well as treatment possibilities, to improve the recognition in the era of the new effective direct antiviral agents. Expand
988 OUTCOMES OF HEPATITIS C SCREENING PROGRAMS TARGETED AT RISK GROUPS HIDDEN IN THE GENERAL POPULATION: A SYSTEMATIC REVIEW
TLDR
A prescreening selection based on risk factors can increase the efficiency of screening in low-prevalence populations, and programs with comparison groups to evaluate effectiveness are needed. Expand
Using mass media and the Internet as tools to diagnose hepatitis C infections in the general population.
TLDR
Internet-mediated risk-based testing for HCV has proved to be a feasible and effective strategy to identify undiagnosed HCV infection in the general population. Expand
Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities.
TLDR
Significant biological and social factors and differences between HIV and HCV suggest that HCV warrants targeted vaccine preparedness research to lay the groundwork for successful implementation of future trials. Expand
A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act.
TLDR
This work sought to address challenges posed by comorbidities in patients with chronic HCV infection and limitations within the health care system, and recommend solutions to maximize the public benefit from ACA and the new drug regimen. Expand
Awareness of Viral Hepatitis B and C Infection among First Year Medical Sciences Students in Jazan University
TLDR
It was found that more than half of the students (64.4%) had basic awareness about hepatitis B and C infection as well as about symptoms, and females depicted higher base knowledge regarding mode of transmission, treatment and vaccination awareness. Expand
Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C.
TLDR
This study aimed to review structural frameworks and key model parameters as reported in current economic evaluations for treatments for chronic hepatitis C, and model the impact of variability across parameters on results. Expand
...
1
2
...

References

SHOWING 1-10 OF 202 REFERENCES
Projecting future complications of chronic hepatitis C in the United States
  • G. Davis, J. Albright, S. Cook, D. Rosenberg
  • Medicine
  • Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2003
TLDR
The prevalence of cirrhosis and the incidence of its complications will increase over the next 10 to 20 years, because the duration of infection increases among those with chronic hepatitis C. Expand
Prevalence of Liver Disease in a Population of Asymptomatic Persons with Hepatitis C Virus Infection
TLDR
The substantial prevalence of abnormal liver histology among asymptomatic persons is a provocative but incomplete rationale for screening for HCV, and the prevalence of infection and the effectiveness of treatment are also important considerations. Expand
Cost-Effectiveness of 6 and 12 Months of Interferon- Therapy for Chronic Hepatitis C
TLDR
The cost-effectiveness of interferon- treatment from the point of view of society was assessed by comparing the number of liver-related deaths, quality-adjusted survival, and costs among the treatment strategies. Expand
Estimates of the Cost-Effectiveness of a Single Course of Interferon-2b in Patients with Histologically Mild Chronic Hepatitis C
TLDR
A decision analytic model was developed to project the immediate responses to treatment and predict the long-term outcomes on the basis of current natural history data to determine whether treatment of histologically mild chronic hepatitis C with a single 6-month course of interferon-2b would affect life expectancy and lifelong costs. Expand
Treatment of Chronic Hepatitis C Virus Infection
TLDR
It is now possible to achieve a cure in nearly 50% of the patients with this infection, and a higher rate of response has been achieved by using the combination of interferon and ribavarin. Expand
Natural history of hepatitis C.
Approximately 85% of persons with acute hepatitis C develop chronic hepatitis as determined by persistently abnormal serum enzymes and/or viremia (hepatitis C virus [HCV] RNA). Both the acute andExpand
Hepatitis B virus/hepatitis C virus coinfection: Epidemiology, clinical features, viral interactions and treatment
TLDR
For coinfected patients with dually‐active HBV/HCV, the optimal regimen for therapy remains unclear although adding oral nucleos(t)ide analogs to pegylated IFN and ribavirin seems a reasonable empiric option. Expand
Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review.
  • D. Prati
  • Medicine
  • Journal of hepatology
  • 2006
TLDR
The published literature concerning HCV transmission through blood transfusions and other unsafe medical procedures is reviewed and the substantial difference in current disease transmission patterns between the northern and southern hemispheres is analysed. Expand
Treatment of chronic hepatitis C virus infection - Dutch national guidelines.
TLDR
This guideline is the establishment of practical guidelines in the evaluation and antiviral treatment of patients with chronic hepatitis C virus (HCV) infection, which includes recommendations for the initial evaluation of patients, the choice and duration of antiviral therapy and the follow-up after antiviral Therapy. Expand
Combination Therapy for Hepatitis C Infection
TLDR
The public health implications of HCV infection have only recently been widely appreciated, as a result of epidemiologic studies that pointed out the magnitude of infection and an alarming increase in morbidity and mortality due to HCV-related disease. Expand
...
1
2
3
4
5
...